{"id":"arry-300-mek-inhibitor-oral","safety":{"commonSideEffects":[{"rate":"30%","effect":"Diarrhea"},{"rate":"20%","effect":"Nausea"},{"rate":"15%","effect":"Vomiting"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"ARRY-300 is a small molecule inhibitor of the MEK1/2 enzyme, which is involved in the MAPK/ERK signaling pathway.","oneSentence":"MEK inhibitor","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T04:54:37.904Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Non-small cell lung cancer"}]},"trialDetails":[{"nctId":"NCT00828165","phase":"PHASE1","title":"A Safety Study of ARRY-300 in Healthy Subjects","status":"COMPLETED","sponsor":"Array Biopharma, now a wholly owned subsidiary of Pfizer","startDate":"2009-01","conditions":"Healthy","enrollment":12}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_1","status":"active","brandName":"ARRY-300, MEK inhibitor; oral","genericName":"ARRY-300, MEK inhibitor; oral","companyName":"Array Biopharma, now a wholly owned subsidiary of Pfizer","companyId":"array-biopharma-now-a-wholly-owned-subsidiary-of-pfizer","modality":"Small molecule","firstApprovalDate":"","aiSummary":"MEK inhibitor Used for Non-small cell lung cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}